FDA Win Boosts Struggling Pharmaceutical Stock
Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug Wegovy landed Food and Drug Administration (FDA) approval to be used in the treatment of liver disease in the U.S. Today's pop comes just weeks after the company slashed its 2025 profit outlook and appointed a new CEO, resulting in a 21.8% bear gap on July 29, its worst drop on record.
Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease
U.S.-listed shares of Novo Nordisk (NVO) gained 4% in premarket trading after the Food and Drug Administration (FDA) approved the pharmaceutical firm's popular weight-loss drug, Wegovy, to treat a serious liver disease.
Novo Nordisk to offer Ozempic for $499 per month
Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients to access authentic Ozempic for $499 per month.
Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
Novo Nordisk said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price through multiple platforms. Patients can pay $499 in cash per month for three dose sizes of Ozempic through the drug's official website, Novo Nordisk's patient assistance program, the company's recently launched direct-to-consumer online pharmacy and drug savings company GoodRx, among other platforms.
Novo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It.
Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and Ozempic for diabetes.
Novo Nordisk shares are rising. The FDA approves another use for Wegovy.
Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy to treat a form of liver disease.
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks.
It's Time To Be All-In On Novo Nordisk
Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin pressures. GLP-1 therapies, especially Ozempic and Wegovy, are driving robust growth, but competition from Eli Lilly and compounded versions present near-term headwinds. Strong fundamentals include industry-leading margins, high ROE, consistent share buybacks, and a fast-growing dividend yield, supporting long-term shareholder value.
Novo Nordisk launches weight-loss drug Wegovy in South Africa
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the country eight months earlier.
A Cure For Novo Nordisk
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47.50 is a strong technical support; I expect stabilization and a gradual recovery from this level.
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
Novo Nordisk: The Falling Knife That Keeps Giving
Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in obesity, cardiovascular, and rare diseases, including promising drugs like oral semaglutide and Mim8. Shareholder returns are supported by strong free cash flow, double-digit profit growth, and disciplined capital expenditures for future expansion.
